| 29.27 0.11 (0.38%) | 09-13 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 34.75 | 1-year : | 40.59 |
| Resists | First : | 29.75 | Second : | 34.75 |
| Pivot price | 28.94 |
|||
| Supports | First : | 28.57 | Second : | 27.85 |
| MAs | MA(5) : | 29.44 |
MA(20) : | 28.89 |
| MA(100) : | 28.55 |
MA(250) : | 28.81  |
|
| MACD | MACD : | 0 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 75.7 |
D(3) : | 84.9 |
| RSI | RSI(14): 53.3 |
|||
| 52-week | High : | 34.11 | Low : | 25.2 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ PFE ] has closed below upper band by 30.6%. Bollinger Bands are 29.3% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 29.33 - 29.48 | 29.48 - 29.63 |
| Low: | 28.65 - 28.8 | 28.8 - 28.95 |
| Close: | 29.03 - 29.27 | 29.27 - 29.51 |
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
Sat, 14 Sep 2024
Pfizer posts trial win in cancer weight loss (NYSE:PFE) - Seeking Alpha
Sat, 14 Sep 2024
PFE: 3 Healthcare Stocks With High Analyst Price Targets - StockNews.com
Fri, 13 Sep 2024
Pfizer Inc. (PFE): A Bull Case Theory - Yahoo Finance
Thu, 12 Sep 2024
Is Pfizer Inc. (PFE) The Most Buzzing Stock To Buy Now? - Insider Monkey
Tue, 10 Sep 2024
Why Pfizer (PFE) Outpaced the Stock Market Today - Yahoo Finance
Tue, 10 Sep 2024
Pfizer Inc. stock outperforms competitors on strong trading day - MarketWatch
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NYSE
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Drug Manufacturers - General
|
|
| Shares Out | 5,670 (M) |
| Shares Float | 5,660 (M) |
| Held by Insiders | 0 (%) |
| Held by Institutions | 67.6 (%) |
| Shares Short | 61,730 (K) |
| Shares Short P.Month | 55,700 (K) |
| EPS | -0.47 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 15.47 |
| Profit Margin | -4.7 % |
| Operating Margin | 22.3 % |
| Return on Assets (ttm) | 0.9 % |
| Return on Equity (ttm) | -2.8 % |
| Qtrly Rev. Growth | 2 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 9.73 |
| EBITDA (p.s.) | 1.75 |
| Qtrly Earnings Growth | -98.2 % |
| Operating Cash Flow | 8,010 (M) |
| Levered Free Cash Flow | 3,440 (M) |
| PE Ratio | -63.64 |
| PEG Ratio | 0.5 |
| Price to Book value | 1.89 |
| Price to Sales | 3 |
| Price to Cash Flow | 20.71 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|